MarketCap
Facebook
X
Telegram
Cutera EBITDA | CUTR
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Cutera
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -148 M | -32.4 M | 5.02 M | -18.8 M | -10.6 M | -12.2 M | 12.1 M | 3.38 M | -3.34 M | -9.28 M | -3.95 M | -5.22 M | -9.8 M | -10.4 M | -9.48 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.1 M | -148 M | -16.9 M |
Quarterly EBITDA Cutera
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.2 M | -21.8 M | -19.4 M | - | -36.2 M | -27.2 M | -23 M | - | -8.24 M | -9 M | -12.1 M | - | 626 K | 2.07 M | 1.16 M | 1.44 M | -155 K | -10.2 M | -11.8 M | -1.93 M | -1.22 M | 1.11 M | -7.62 M | -5.49 M | -149 K | -1.61 M | -4.5 M | 4.54 M | 6.97 M | 2.22 M | -1.16 M | 4.44 M | 2.27 M | -932 K | -1.93 M | 2 M | -72 K | -1.31 M | -3.28 M | -1.59 M | -1.55 M | -2.18 M | -3.32 M | -340 K | -1 M | 23 K | -2 M | 1.07 M | 78 K | -753 K | -4.92 M | -934 K | -2.14 M | -2.54 M | -3.85 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.97 M | -36.2 M | -4.68 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B |  USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Vapotherm
VAPO
|
-34.1 M | - | 6.72 % | $ 34 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | - | - | $ 162 M |  France |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
Natus Medical Incorporated
NTUS
|
51.9 M | - | 1.94 % | $ 1.05 B | USA |
 |
Titan Medical
TMDI
|
-31 M | - | -26.32 % | $ 19.6 M |  Canada |
 |
Acutus Medical
AFIB
|
240 K | - | -26.83 % | $ 2.62 M | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
-47 M | - | 0.28 % | $ 270 M | USA |
 |
AxoGen
AXGN
|
-1.19 M | $ 48.28 | 2.51 % | $ 2.22 B | USA |
 |
Bruker Corporation
BRKR
|
288 M | $ 58.5 | 0.13 % | $ 8.88 B | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-32.8 M | $ 74.29 | 2.75 % | $ 2.2 B |  Costa-rica |
 |
Nevro Corp.
NVRO
|
-118 M | - | - | $ 217 M | USA |
 |
Abiomed
ABMD
|
169 M | - | - | $ 17.2 B | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Abbott Laboratories
ABT
|
9.49 B | $ 108.33 | 0.19 % | $ 189 B | USA |
 |
Aethlon Medical
AEMD
|
-6.97 M | $ 1.82 | 6.04 % | $ 1.23 M | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 6.49 | 1.09 % | $ 877 M | USA |
 |
Align Technology
ALGN
|
783 M | $ 158.64 | 0.03 % | $ 11.5 B | USA |
 |
Apyx Medical Corporation
APYX
|
-5.79 M | $ 3.05 | 0.32 % | $ 125 M | USA |
 |
Accuray Incorporated
ARAY
|
-18.5 M | $ 0.27 | 0.3 % | $ 33.1 M | USA |
 |
Alphatec Holdings
ATEC
|
-4.64 M | $ 9.45 | 1.29 % | $ 1.42 B | USA |
 |
Avanos Medical
AVNS
|
-22.7 M | $ 24.99 | - | $ 1.16 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-13.6 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Butterfly Network
BFLY
|
-79.7 M | $ 7.36 | 0.96 % | $ 1.82 B | USA |
 |
Bio-Rad Laboratories
BIO
|
213 M | $ 386.11 | 0.05 % | $ 10.5 B | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
4.98 B | $ 47.8 | 1.83 % | $ 70.8 B | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
25.2 M | $ 8.47 | 0.71 % | $ 618 M | Israel |
 |
ClearPoint Neuro
CLPT
|
-23.4 M | $ 13.96 | 0.67 % | $ 395 M | USA |
 |
CONMED Corporation
CNMD
|
120 M | $ 49.32 | 0.02 % | $ 1.53 B | USA |
 |
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.35 | 0.03 % | $ 21.8 M | USA |
 |
Delcath Systems
DCTH
|
898 K | $ 16.48 | 1.1 % | $ 590 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |